Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown, +7

Journal of Clinical Oncology

Phase I/ii StudyMut Braf MelanomaImmunotherapeuticsCancer BiologyTumor Biology +18

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer, +18

Annals of Oncology

Pancreatic CancerMedicinePharmacologyPlatinum-resistant Ovarian CancerCancer Treatment +4

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

J. R. Infante, G. S. Falchook, Donald P. Lawrence, +17

Journal of Clinical Oncology

Brafi ExposurePhase I/ii StudyImmunologyPharmacotherapyImmunotherapeutics +17

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

J. R. Infante, Leslie A. Fecher, Sujatha Nallapareddy, +7

Journal of Clinical Oncology

PathologyPharmacotherapyTumor BiologyEfficacy ResultsOral Mek 1/2 +19

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

H. Burris, Jordi Rodón, Shaleekha Sharma, +7

Journal of Clinical Oncology

Chemoprevention StrategyFirst-in-human PhasePathologyAdvanced Solid TumorsTumor Biology +15

Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

Andrés Cervantes, María Alsina, Josep Tabernero, +17

Journal of Clinical Oncology

Solid TumorsLiver InvolvementNovel Rnai TherapeuticPathologyPharmacotherapy +15

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.

Howard A. Burris, L.L. Siu, J. R. Infante, +14

Journal of Clinical Oncology

PharmacotherapyPten LossFirst-in-human StudyTumor BiologyPharmacological Study +14

Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)

J. R. Infante, Fadi Braiteh, Leisha A. Emens, +8

Annals of Oncology

Advanced Ovarian CancerMedicineGynecologyAnti-cancer AgentCancer Treatment +5

Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

Branimir I. Šikić, S. Gail Eckhardt, G. Gallant, +10

Journal of Clinical Oncology

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).

Katherine L. Nathanson, Alison Martin, Richard Letrero, +11

Journal of Clinical Oncology

Pten MutationPathologyCancer BiologyTumor BiologyPten Alteration +14